These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 16389293)
1. Ropinirole, a non-ergoline dopamine agonist. Jost WH; Angersbach D CNS Drug Rev; 2005; 11(3):253-72. PubMed ID: 16389293 [TBL] [Abstract][Full Text] [Related]
2. Ropinirole: current status of the studies. Jost WH J Neurol; 2004 Sep; 251 Suppl 6():VI/13-8. PubMed ID: 15675719 [TBL] [Abstract][Full Text] [Related]
3. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Kuzel MD Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505 [TBL] [Abstract][Full Text] [Related]
4. Ropinirole in the symptomatic treatment of Parkinson's disease. Brooks DJ; Torjanski N; Burn DJ J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630 [TBL] [Abstract][Full Text] [Related]
5. Ropinirole: a review of its use in the management of Parkinson's disease. Matheson AJ; Spencer CM Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932 [TBL] [Abstract][Full Text] [Related]
7. Clinical studies with ropinirole in Parkinson's disease and RLS. Jost WH; Angersbach D; Rascol O J Neurol; 2006 Aug; 253 Suppl 4():IV16-21. PubMed ID: 16944351 [TBL] [Abstract][Full Text] [Related]
8. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Iskedjian M; Einarson TR Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573 [TBL] [Abstract][Full Text] [Related]
12. Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. Taylor AC; Beerahee A; Citerone DR; Cyronak MJ; Leigh TJ; Fitzpatrick KL; Lopez-Gil A; Vakil SD; Burns E; Lennox G Pharmacotherapy; 1999 Feb; 19(2):150-6. PubMed ID: 10030765 [TBL] [Abstract][Full Text] [Related]
13. Side effects of ropinirole in patients with idiopathic Parkinson's disease. Titlic M; Tonkic A; Jukic I; Lusic I; Dikanovic M Bratisl Lek Listy; 2008; 109(6):273-5. PubMed ID: 18700440 [TBL] [Abstract][Full Text] [Related]
14. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. Thalamas C; Taylor A; Brefel-Courbon C; Eagle S; Fitzpatrick K; Rascol O Eur J Clin Pharmacol; 1999 Jun; 55(4):299-303. PubMed ID: 10424323 [TBL] [Abstract][Full Text] [Related]
15. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K; Lyons KE Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805 [TBL] [Abstract][Full Text] [Related]
16. D-512, a novel dopamine D Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675 [TBL] [Abstract][Full Text] [Related]
17. [Dopaminergic agonists in the treatment of Parkinson's disease]. Supiot F; Sternon J; Zegers de Beyl D Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495 [TBL] [Abstract][Full Text] [Related]
18. Ropinirole treatment for restless legs syndrome. Chitnis S Expert Opin Drug Metab Toxicol; 2008 May; 4(5):655-64. PubMed ID: 18484922 [TBL] [Abstract][Full Text] [Related]
19. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. Buchwald B; Angersbach D; Jost WH Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044 [TBL] [Abstract][Full Text] [Related]